The serious implications of long-term asbestos exposure By James L. Ferraro | Asbestos Exposure & Claims | Last Modified on Feb 23, 2026 Read More
Purdue Pharma could pay $13 billion in... By James L. Ferraro | Pharmaceutical Litigation | Last Modified on Feb 27, 2026 Read More
Elmiron use linked to loss of vision:... By James L. Ferraro | Pharmaceutical Litigation | Last Modified on Feb 20, 2026 Read More
Mesothelioma: Researchers announce hopeful discovery By James L. Ferraro | Mesothelioma | Last Modified on Feb 20, 2026 Read More
Can Zantac transfer from a pregnant woman... By James L. Ferraro | Zantac Recall | Last Modified on Feb 20, 2026 Read More
Zantac recall: FDA says do not take... By James L. Ferraro | Zantac Recall | Last Modified on Feb 20, 2026 Read More
Surviving mesothelioma: What happens next? By James L. Ferraro | Mesothelioma | Last Modified on Apr 03, 2026 Read More
Purdue Pharma faces $13 billion in penalties... By James L. Ferraro | Pharmaceutical Litigation | Last Modified on Feb 20, 2026 Read More
Have current events made the opioid epidemic... By James L. Ferraro | Pharmaceutical Litigation | Last Modified on Feb 20, 2026 Read More
Does asbestos exposure always lead to mesothelioma? By James L. Ferraro | Asbestos Exposure & Claims | Last Modified on Feb 20, 2026 Read More
Mesothelioma treatment research continues to show promise By James L. Ferraro | Mesothelioma | Last Modified on Feb 27, 2026 Read More
Zantac recall issues: Understanding the signs of... By James L. Ferraro | Zantac Recall | Last Modified on Feb 20, 2026 Read More